We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory

    Susanne B Haga

    *Author for correspondence: Tel.: +1 919 684 0325;

    E-mail Address: susanne.haga@duke.edu

    Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, 304 Research Drive, Durham, NC 27708, USA

    Search for more papers by this author

    &
    Yiling Liu

    Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, 304 Research Drive, Durham, NC 27708, USA

    Search for more papers by this author

    Published Online:13 Jun 2019https://doi.org/10.2217/pgs-2019-0006

    Abstract

    Aims: Patients’ use of and experience with pharmacogenetic (PGx) testing may be impacted by several factors including patient and provider knowledge, health status, and perceived understanding of results. Materials & Methods: We conducted an online survey of individuals who had subscribed to a newsletter service offered by a US commercial PGx testing company, Genelex. Results: We find that about half of respondents that had PGx testing reviewed one or more of the lab’s web-pages, 43% believed they understood the test results very well, but 40% did not know or could not recall whether their provider had changed their prescription based on the test result. Conclusions: There was limited use of the laboratory’s online resources by respondents undergoing PGx testing. Increased awareness of the website may improve understanding of test results and facilitate discussions with providers about medication changes.

    References

    • 1. Metcalfe SA , Martyn M , Ames A et al. Informed decision making and psychosocial outcomes in pregnant and nonpregnant women offered population fragile X carrier screening. Genet. Med. 19(12), 1346–1355 (2017).
      MedlineGoogle Scholar
    • 2. Beulen L , Van Den Berg M , Faas BH et al. The effect of a decision aid on informed decision-making in the era of non-invasive prenatal testing: a randomised controlled trial. Eur. J. Hum. Genet. 24(10), 1409–1416 (2016).
      MedlineGoogle Scholar
    • 3. Burns C , James C , Ingles J . Communication of genetic information to families with inherited rhythm disorders. Heart Rhythm. 15(5), 780–786 (2018).
      MedlineGoogle Scholar
    • 4. Lerner B , Roberts JS , Shwartz M , Roter DL , Green RC , Clark JA . Distinct communication patterns during genetic counseling for late-onset Alzheimer's risk assessment. Patient Educ. Couns. 94(2), 170–179 (2014).
      MedlineGoogle Scholar
    • 5. Ostergren JE , Gornick MC , Carere DA et al. How well do customers of direct-to-consumer personal genomic testing services comprehend genetic test results? Findings from the Impact of Personal Genomics Study. Public Health Genomics 18(4), 216–224 (2015).
      MedlineGoogle Scholar
    • 6. Haga SB , Moaddeb J , Mills R , Patel M , Kraus W , Allen Lapointe NM . Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics 16(17), 1931–1941 (2015).
      CASGoogle Scholar
    • 7. Haga SB , Tindall G , O'Daniel JM . Public perspectives about pharmacogenetic testing and managing ancillary findings. Genet. Test Mol. Biomarkers 16(3), 193–197 (2012).
      MedlineGoogle Scholar
    • 8. Almomani B , Hawwa AF , Goodfellow NA , Millership JS , McElnay JC . Pharmacogenetics and the print media: what is the public told? BMC Med. Genet. 16, 32 (2015).
      MedlineGoogle Scholar
    • 9. Caudle KE , Gammal RS , Whirl-Carrillo M , Hoffman JM , Relling MV , Klein TE . Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am. J. Health Syst. Pharm. 73(23), 1977–1985 (2016).
      Medline CASGoogle Scholar
    • 10. Hoffman JM , Dunnenberger HM , Kevin Hicks J et al. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). J. Am. Med. Inform. Assoc. 23(4), 796–801 (2016).
      MedlineGoogle Scholar
    • 11. Weitzel KW , Aquilante CL , Johnson S , Kisor DF , Empey PE . Educational strategies to enable expansion of pharmacogenomics-based care. Am. J. Health Syst. Pharm. 73(23), 1986–1998 (2016).
      Medline CASGoogle Scholar
    • 12. Weitzel KW , McDonough CW , Elsey AR , Burkley B , Cavallari LH , Johnson JA . Effects of using personal genotype data on student learning and attitudes in a pharmacogenomics course. Am. J. Pharm. Educ. 80(7), 122 (2016).
      MedlineGoogle Scholar
    • 13. Roederer MW , Kuo GM , Kisor DF et al. Pharmacogenomics competencies in pharmacy practice: a blueprint for change. J. Am. Pharm. Assoc. 57(1), 120–125 (2017).
      MedlineGoogle Scholar
    • 14. Heale BSE , Khalifa A , Stone BL , Nelson S , Del Fiol G . Physicians' pharmacogenomics information needs and seeking behavior: a study with case vignettes. BMC Med. Inform. Decis. Mak. 17(1), 113 (2017).
      MedlineGoogle Scholar
    • 15. Romagnoli KM , Boyce RD , Empey PE , Adams S , Hochheiser H . Bringing clinical pharmacogenomics information to pharmacists: a qualitative study of information needs and resource requirements. Int. J. Med. Inform. 86, 54–61 (2016).
      MedlineGoogle Scholar
    • 16. Kobayashi LC , Smith SG . Cancer fatalism, literacy, and cancer information seeking in the American Public. Health Educ. Behav. 43(4), 461–470 (2016).
      MedlineGoogle Scholar
    • 17. Haga SB , Mills R , Moaddeb J . Evaluation of a pharmacogenetic educational toolkit for community pharmacists. Pharmacogenomics 17(14), 1491–1502 (2016).
      CASGoogle Scholar
    • 18. Mills R , Haga SB . Qualitative user evaluation of a revised pharmacogenetic educational toolkit. Pharmgenomics Pers. Med. 11, 139–146 (2018).
      MedlineGoogle Scholar
    • 19. Mills R , Ensinger M , Callanan N , Haga SB . Development and initial assessment of a patient education video about pharmacogenetics. J. Pers. Med. 7(2), pii:E4 (2017).
      MedlineGoogle Scholar
    • 20. Haga SB . Primary care physicians' knowledge of and experience with pharmacogenetic testing. Pharmgenomics Pers. Med. 82(4), 388–394 (2012).
      CASGoogle Scholar
    • 21. Hull LE , Lynch KG , Oslin DW . VA Primary care and mental health providers' comfort with genetic testing: survey results from the PRIME care study. J. Gen. Intern. Med. 34(6), 799–801 (2019).
      MedlineGoogle Scholar
    • 22. Stanek EJ , Sanders CL , Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450–458 (2012).
      Medline CASGoogle Scholar